We employed global untargeted label-free quantitative expression proteomics as a biomarker discovery tool to investigate and better our understanding of the underlying pathophysiological alterations caused by deficient CAII, as well as the potential mechanistic action of fluconazole as a CA activator in the restoration of inadequate osteogenesis in osteopetrosis patients. Here, CA2 is linked to osteopetrosis.